info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Thrombus Treatment Companies

The treatment of thrombus (blood clot) involves a range of medications, interventions, and therapies aimed at preventing the clot from growing, breaking loose, or causing complications such as deep vein thrombosis (DVT) or pulmonary embolism. Several pharmaceutical companies develop and manufacture medications for thrombus treatment.

Thrombus Treatment Key CompaniesLatest Thrombus Treatment Companies Update



  • June 2023: The Lightning Bolt 7 technology, developed by Penumbra, Inc. PEN, is now available. It is used to quickly remove blood clots using modulated aspiration. Penumbra's latest innovation is a computer-assisted thrombectomy service that uses cutting-edge imaging and AI in conjunction with minimally invasive tools to treat vascular disorders including stroke. New aspiration technology and an enhanced microprocessor algorithm enable Lightning Bolt 7 technology to differentiate between a blood clot and normal blood flow. Modulated aspiration at the catheter's tip facilitates rapid and thorough clot removal. The technology is meant to provide a safety profile that, when coupled with the speed and efficiency of clot removal, will encourage an endovascular-first strategy prior to open surgery for a wider variety of situations.




  • May 2023: Asundexian, an experimental medication developed by Bayer, was recently awarded Fast Track Designation by the U.S. FDA for the treatment and prevention of stroke and systemic embolism in persons with atrial fibrillation (AF). This comes after asundexian received its first U.S. FDA Fast Track Designation in 2022, this time for the treatment of patients who have had a non-cardioembolic ischemic stroke. Blood coagulation involves the conversion of a protein called Factor XI into an active enzyme called Factor XIa. By selectively inhibiting FXIa, we can prevent the production of pathological thrombi while sparing the recovery of physiological arterial wall damage. The antithrombotic drug asundexian is now being studied for its potential as an enhanced therapy option in thrombosis prevention.


List of Thrombus Treatment Key companies in the market

  • Teva Pharmaceutical Industries Ltd. (Israel)

  • AngioDynamics Inc. (US)

  • Bristol-Myers Squibb Company (US)

  • Pfizer Inc. (US)

  • Johnson & Johnson Services Inc. (US)

  • Sanofi S.A. (France)

  • Daiichi Sankyo Company, Limited (Tokyo)

  • Boehringer Ingelheim International GmbH (Germany)

  • Aspen Pharmacare Holdings Limited (US)

  • Bayer AG (Germany)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.